Indications
Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.
Composition
- Active substance
- insulin glargine, lixisenatide
- International name (INN)
- insulin glargine;lixisenatide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Suliqua
- Active substance
- insulin glargine, lixisenatide
- ATC code
- A10AE54
- Therapeutic area
- Diabetes Mellitus, Type 2